<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360889</url>
  </required_header>
  <id_info>
    <org_study_id>MDA-1</org_study_id>
    <nct_id>NCT04360889</nct_id>
  </id_info>
  <brief_title>Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities</brief_title>
  <official_title>Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryazan State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryazan State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center, open, prospective, randomized, controlled clinical trial will include 120&#xD;
      patients with lower limb lymphedema who undergo treatment in an office-based vascular lab at&#xD;
      the Ryazan regional clinical cardiology dispensary, Ryazan, Russia. The patients will be&#xD;
      recruited by the staff of the Department of cardiovascular, endovascular, operative surgery,&#xD;
      and topographic anatomy, Ryazan state I.P. Pavlov medical university, Russia. The study will&#xD;
      include patients who meet the inclusion criteria and do not meet the exclusion criteria.&#xD;
      Patients will be divided into 4 groups, 30 subjects each. Group 1-patients with lower limb&#xD;
      lymphedema who will receive conservative therapy with elastic compression and an antioxidant&#xD;
      (Tocopherol-400 IU/day); Group 2-patients with lower limb lymphedema who will receive&#xD;
      conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids&#xD;
      expressed as hesperidin)-1000mg/day) in addition to elastic compression; Group 3-patients&#xD;
      with lower limb lymphedema who will be treated with elastic compression; Group 4- healthy&#xD;
      volunteers with no history or clinical signs of venous or lymphatic disease; The duration of&#xD;
      this study for each subject will be a maximum of 90 days. Pre-screening and screening will&#xD;
      involve 200 subjects with a total of 120 subjects who will be randomized into the study.&#xD;
      Peripheral blood samples will be collected to evaluate the activity of biochemical markers of&#xD;
      endothelial function; the quality of life will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research methods:&#xD;
&#xD;
        1. Physical examination;&#xD;
&#xD;
        2. peripheral blood sampling (assessment of the concentration of the markers of endothelial&#xD;
           dysfunction, including malondialdehyde (MDA), superoxide dismutase (SD), catalase( CAT),&#xD;
           glutathione peroxidase (GP). MDA concentration will be determined with a competitive&#xD;
           enzyme immunoassay (ELISA), which will be performed using a General MDA assessment kit&#xD;
           (manufacturer: USCN Life Science Inc. US-CEA597GE). CAT concentration will be determined&#xD;
           using a competitive enzyme immunoassay (ELISA), which will be performed with a kit for&#xD;
           quantitative in vitro assessment of catalase (manufacturer: USCN Life Science Inc.&#xD;
           US-SEC418Hu). GP concentration will be determined with a competitive enzyme immunoassay&#xD;
           (ELISA), which will be performed using a glutathione peroxidase quantification set&#xD;
           (abfrontier supplier, Republic of Korea - LF- EK0110). SOD concentration will be&#xD;
           determined using a competitive enzyme immunoassay (ELISA), which will be performed using&#xD;
           a total superoxide dismutase detection kit (supplier Cayman Chemical Company, US -&#xD;
           706002).&#xD;
&#xD;
        3. Lower limb venous sonography with a linear 5-13 MHz probe;&#xD;
&#xD;
        4. Patient questionnaire using a Russian-language version of the Quality of life&#xD;
           questionnaire &quot;SF-36 Health Status Survey&quot;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The malleolar volume of the limb</measure>
    <time_frame>90 days</time_frame>
    <description>The circumference at the level of the narrowest part of the lower leg, measured in centimeters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Level Of Catalase</measure>
    <time_frame>90 days</time_frame>
    <description>Biochemical indicator of the functional state of the endothelium. Catalase concentration will be determined using a competitive enzyme immunoassay (ELISA), which will be performed with a kit for quantitative in vitro assessment of catalase (manufacturer: USCN Life Science Inc. US-SEC418Hu). Unit of measurement ng / ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Level Of Superoxide Dismutase</measure>
    <time_frame>90 days</time_frame>
    <description>Biochemical indicator of the functional state of the endothelium. Superoxide Dismutase concentration will be determined using a competitive enzyme immunoassay (ELISA), which will be performed using a total superoxide dismutase detection kit (supplier Cayman Chemical Company, US - 706002). Unit of measurement UI / ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Level Of Glutathione Peroxidase</measure>
    <time_frame>90 days</time_frame>
    <description>Biochemical indicator of the functional state of the endothelium. Glutathione Peroxidase concentration will be determined with a competitive enzyme immunoassay (ELISA), which will be performed using a glutathione peroxidase quantification set (abfrontier supplier, Republic of Korea - LF- EK0110). Unit of measurement ng / ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of Malondialdehyde</measure>
    <time_frame>90 days</time_frame>
    <description>Biochemical indicator of the functional state of the endothelium. Malondialdehyde concentration will be determined with a competitive enzyme immunoassay (ELISA), which will be performed using a General MDA assessment kit (manufacturer: USCN Life Science Inc. US-CEA597GE). Unit of measurement ng / ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life indicators: questionnaire</measure>
    <time_frame>90 days</time_frame>
    <description>Patient questionnaire using a Russian-language version of the Quality of life questionnaire &quot;Short Form-36 Health Status Survey&quot;. 8 indicators. Indicator from 0 to 100. Higher scores mean a better outcome.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lower Extremity Lymphedema</condition>
  <arm_group>
    <arm_group_label>Tocopherol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micronised purified flavonoid fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elastic compression</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with lower limb lymphedema who will be treated with elastic compression - 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)</intervention_name>
    <description>Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day</description>
    <arm_group_label>Micronised purified flavonoid fraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocopherol</intervention_name>
    <description>patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)</description>
    <arm_group_label>Tocopherol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elastic compression</intervention_name>
    <description>patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression</description>
    <arm_group_label>Elastic compression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Secondary lymphedema of the lower extremities&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  varicose veins of the lower extremities,&#xD;
&#xD;
          -  deep vein thrombosis,&#xD;
&#xD;
          -  post-thrombotic disease,&#xD;
&#xD;
          -  obliterating&#xD;
&#xD;
          -  atherosclerosis of the lower limb arteries,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  lactation,&#xD;
&#xD;
          -  cancer,&#xD;
&#xD;
          -  acute violation of cerebral circulation in the anamnesis,&#xD;
&#xD;
          -  trophic lesions of the skin of the lower extremities,&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  an infectious disease with a history of three months prior to inclusion in the study,&#xD;
&#xD;
          -  heart failure,&#xD;
&#xD;
          -  kidney failure,&#xD;
&#xD;
          -  pulmonary insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Denis A. Maksaev</last_name>
    <phone>+79156005484</phone>
    <email>denma1804@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ryazan State Medical University</name>
      <address>
        <city>Ryazan'</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis A. Maksaev</last_name>
      <phone>+79156005484</phone>
      <email>denma1804@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial dysfunction</keyword>
  <keyword>secondary lymphedema of the lower extremities</keyword>
  <keyword>antioxidants</keyword>
  <keyword>micronized purified flavonoid fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

